Alltrna

Alltrna is the world’s first transfer RNA (tRNA) platform company, and we are unlocking the vast therapeutic potential within #tRNA biology.

[Alltrna @alltrna]

Precision in genetic medicine does not always have to mean one gene, one drug. It can also mean one mechanism, one drug.

In this Q&A with Advancing RNA, Alltrna CMO Nerissa Kreher discusses how engineered tRNA therapeutics are being developed to address a shared genetic error, like premature stop codons, with the potential to support mutation-defined approaches across many diseases.

https://t.co/WrQNFXxCwW

#tRNA #StopCodonDisease

[Alltrna @alltrna]

At Alltrna, the best science happens when people feel connected to something bigger than the lab. We recently set up two AeroGardens, a traditional seed sowing station, and a sunny corner dedicated to dwarf cherry tomatoes, basil, and mint.

Alltrnators came together to plant, decorate their pots, and nurture something new.

[Alltrna @alltrna]

In approximately 10% of rare genetic diseases, the gene and RNA are present, but translation stops before a full-length protein can be made. In a new Q&A with Technology Networks, Alltrna CSO Dave Hava explains how engineered tRNA therapeutics can address shared translation errors by acting within the cell’s native translation machinery at the point where mRNA is decoded into protein.

This creates the potential for mutation-defined drug development to restore full-length protein production across many rare and ultra-rare diseases that share the same genetic variant.

Read more in @Tech_Networks: https://t.co/T7NYgLsrtP

[Alltrna @alltrna]

At ASGCT 2026, Alltrna will give an oral presentation highlighting the potential of engineered tRNA therapeutics to restore full-length protein production across rare and ultra-rare genetic disorders caused by premature termination codons.

The presentation will feature preclinical data from AP003, Alltrna’s lead clinical candidate, in phenylketonuria and methylmalonic acidemia models. The data support advancement of a single engineered tRNA therapeutic through a basket-enabled clinical strategy across liver inborn errors of metabolism that share an Arg-TGA premature termination codon.

The full #ASGCT26 abstract is available online: https://t.co/H0OnarewBW

[Alltrna @alltrna]

Rare disease research often calls for clinical development strategies that can work across small, heterogeneous patient populations. Alltrna CMO Nerissa Kreher will give a keynote about how basket and umbrella trial approaches can help address these challenges, from recruitment and evidence generation to operational execution and regulatory alignment.

Her talk at COG is Tuesday, April 28 at 9:30 am ET. See the agenda for more details: https://t.co/fYPB48Lq8d

[Alltrna @alltrna]

The Chief Medical Officer role is shaped by context, including the distinct demands of private and public biotech companies.

Alltrna CMO Nerissa Kreher will share her perspective at The CMO Summit 360º during Roundtable #5 on Tuesday, April 14, from 2:25 to 3:10 p.m. in Boston.

https://t.co/Zd2oMBuS35

[Alltrna @alltrna]

Alltrna has received approval to initiate the first clinical trial of a tRNA therapeutic! It is more than a company milestone, it is a first step toward a different model for rare disease drug development, one built around shared genetic mutations instead of treating one disease at a time.

Read the press release: https://t.co/wQQetWu9Cm

#tRNA #StopCodonDisease #rarediseases #clinicaltrials

[Alltrna @alltrna]

This morning in Endpoints, Alltrna shared the news that a tRNA therapeutic is entering the clinic for the first time. One tRNA therapeutic could potentially treat patients across many diseases linked by the same genetic mutation.

Scientists have understood the role of tRNA in protein translation for decades, but what did not exist was the ability to engineer, optimize, manufacture, and deliver tRNAs as medicines.

Read Endpoints’ exclusive look at how this milestone could open the door to a more scalable path for developing medicines across rare genetic diseases.

https://t.co/3t2inTmnvI

#tRNA #StopCodonDisease #rarediseases #clinicaltrials

[Alltrna @alltrna]

At Alltrna, we know progress is shaped by the people who inspire, support, and lead us. This Women’s History Month, our team is honoring the women who have made a lasting impact on our lives and work by sharing their stories and celebrating their influence.

[Alltrna @alltrna]

As we prepare to advance our lead program into the clinic, we’re pleased to announce that Joanne Protano has been elevated to President and CFO and will guide Alltrna into its next phase as a clinical-stage company.

Joanne has been instrumental in shaping Alltrna’s strategy and operations, and her deep knowledge of the business and commitment to our mission position the company strongly for this next chapter. @afzelius_lovisa, Alltrna Co-founder and Board Chair, will transition into the role of Executive Chair, working closely with Joanne and the Alltrna leadership team.

Michelle Werner has made the decision to step down as CEO. We thank her for her leadership and the strong foundation she helped build for our tRNA platform. We are pleased she will continue with Alltrna as an advisor and member of the Board of Directors.

We remain focused on advancing transformative tRNA medicines for patients. The momentum continues, and we’re energized for what’s ahead.

[Alltrna @alltrna]

Understanding how specific gene variants shape PKU was the focus of our poster at the NPKUA 2026 Scientific Conference. Our Chief Medical Officer, Nerissa Kreher, MD, presented genotype–phenotype insights that help deepen our understanding of disease biology at the variant level.

For families considering genetic testing, even after a diagnosis, this video may be helpful: https://t.co/GbF1MEbGK1

Thank you to the @NPKUA_Info for convening this important meeting and for partnering with @RareDiseases to develop this educational video.

#PKU #rarediseases #genetics #clinicalresearch #tRNA #StopCodonDisease

[Alltrna @alltrna]

During #RareDiseaseWeek, we’re highlighting the role of genetic testing. For many families, this is an important next step, even after diagnosis, because knowing the specific gene variant may inform care and open access to clinical studies.

Identifying the specific gene variant may:
• Clarify the biological cause of disease
• Inform ongoing care decisions
• Highlight implications for relatives
• Support access to clinical research and mutation-defined studies

Learn more here: https://t.co/GbF1MEbGK1

We are proud to have provided funding to support these educational videos, from the @RareDiseases, which were created in English and Spanish in partnership with the @NPKUA_Info and @OsmosisMed.

#RareDiseaseWeek #rarediseases #genetictesting #clinicalresearch #tRNA #StopCodonDisease

[Alltrna @alltrna]

What if rare disease drug development is at the same turning point oncology reached two decades ago?

On the IDEA Collider podcast, Michelle Werner reflects on how oncology drug development was transformed once we began organizing around shared genetic drivers rather than tumor type. That shift led to targeted therapies, basket trials, and mutation-defined approvals that changed both clinical practice and patient outcomes.

Approximately 10 percent of all genetic diseases are caused by premature termination codons. By engineering tRNA therapeutics to address this shared mutation, Alltrna is advancing a strategy designed to move beyond one drug, one disease and toward mutation-defined drug development across many rare genetic diseases.

The question now is not about what tRNA biology can do. It is whether we are ready to build clinical and regulatory pathways that match it and expand what is possible for patients.

Listen to the full conversation to hear Michelle’s perspective on leadership, urgency, and why this may be the inflection point for rare genetic diseases.

https://t.co/cCzm9jaaj2

[Alltrna @alltrna]

In recognition of the International Day of Women and Girls in Science, members of the Alltrna team joined @FlagshipPioneer for a conversation with Sally Kornbluth, President of MIT. Her candid reflections on leadership, career pivots, and the importance of staying curious were both relatable and energizing.

What resonated most was the reminder that authenticity matters, because in science, progress is driven as much by people as it is by ideas. The courage to ask questions, to acknowledge uncertainty, and to grow alongside one another is part of how meaningful science gets done.

#IDWGS #WomenInSTEM #tRNA #StopCodonDisease #rarediseases

[Alltrna @alltrna]

Some conversations stay with you because of the people in the room. Thank you to eWIB Greater Boston for convening such a thoughtful fireside discussion, and to everyone who joined and contributed to a candid exchange on leadership, mentorship, and responsibility in biotech.

We’re grateful to be part of a community that makes space for conversations like this.

To learn more about eWIB, visit Women In Bio - Engage. Educate. Empower: https://t.co/YwnUa46Vtn

[Alltrna @alltrna]

Designing tRNA therapeutics starts with representing tRNAs as they operate, including their structural and chemical features, not just their sequence. That is why we are excited to collaborate with A*STAR – Agency for Science, Technology and Research to advance how chemically modified nucleotides on tRNA are represented in molecular simulations.

Naturally occurring tRNAs rely on a rich landscape of chemical modifications on individual nucleotides to achieve their structure, stability, and function, and those same features are important when designing tRNAs as therapeutics.

Conducted under A*STAR’s established collaboration with @FlagshipPioneer, our work together aims to broaden the technical toolkit that supports the design and evaluation of therapeutic tRNAs.

#tRNA #StopCodonDisease #rarediseases #ASTAR

[Alltrna @alltrna]

“We’re not looking at genes or proteins one at a time. We’re looking at the shared mutations across many different genes, and that changes how you think about scaling drug development for rare disease.”

Hear Alltrna CEO Michelle Werner discuss how mutation defined strategies and basket trial thinking could expand access for patients who are often left out of traditional drug development models, and what this approach could unlock for the future of genetic medicines, on this special episode of The Genetics Podcast, recorded live at #JPM26 at @FlagshipPioneer studios.

[Sano Genetics @sanogenetics]

🎙️Tune in to Episode 223 of #TheGeneticsPodcast 🚀

This week, we’re joined for a special recording at the Flagship Pioneering studio during JPM 2026 by Michelle Werner, CEO of Alltrna, and Mike Severino, CEO of Tessera Therapeutics. Listen in to hear how engineered tRNAs and RNA-based gene writing are creating new paths to treat genetic diseases, why both platforms are entering the clinic this year with strong preclinical confidence, and what it takes to translate these approaches into scalable therapies that meet real patient needs.

Available here👇

🎧 https://t.co/Nffyayym7i
📽️ https://t.co/mDB3UOP4OS

#PrecisionMedicine #GeneticMedicine #RareDisease #GeneEditing #JPM2026 #DrugDevelopment